Overview

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed

Trial end date:
2010-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate, after 1 week of dosing, the efficacy and safety of PT003 compared with its individual components (PT001 and PT005), placebo and two active comparators to demonstrate superiority of the combination to its components, and to assess the relative contribution of the components compared with placebo, in patients with moderate to very severe COPD.

Phase:

Phase 2

Details

Lead Sponsor:

Pearl Therapeutics, Inc.

Treatments:

Bromides
Formoterol Fumarate
Tiotropium Bromide